Држава: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
N'n'-ethylene-(l,l) -dicysteine
CIS bio International
V09CA
N'n'-ethylene-(l,l) -dicysteine
2 milligram(s)
Kit for radiopharmaceutical preparation
Product subject to prescription which may not be renewed (A)
Technetium (99mTc) compounds
Marketed
2013-11-15
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Edicis 2mg kit for radiopharmaceutical preparation 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Edicis vial contains 2 mg of ethylenedicysteine. The radionuclide is not part of the kit. Excipients with known effect Each Edicis vial contains 3.5 mg of sodium. Each buffer vial contains 5.2 mg of potassium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Kit for radiopharmaceutical preparation Edicis (red strip): White or slightly yellow powder Reducing agent (yellow strip): White or slightly yellow powder, to be reconstituted. Buffer (green strip): White or yellow paste, to be reconstituted. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. After radiolabelling with sodium pertechnetate ( 99m Tc) solution and reconstitution, the solution of technetium ( 99m Tc) - ethylenedicysteine obtained, is indicated in adults for dynamic scintigraphy, in the following settings: - Evaluation of nephropathies and uropathies especially for assessing relative kidney function, renal morphology, and renal perfusion - Drainage of the upper urinary tract. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION This medicinal product is intended for use in designated nuclear medicine facilities only, and should only be handled by authorised personnel. Posology _Adults_ The recommended activity for a patient of 70 kg average body weight is between 90 MBq and 120 MBq. _Elderly population_ No adaptation is recommended I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Прочитајте комплетан документ